Mobile Site ›
Print Friendly View

Test ID: TAE    
Therapeutic Antibody by Flow Cytometry

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting cell-surface antigens on malignant cells that are potential therapeutic antibody targets

 

Determining the eligibility of patients for monoclonal antibody therapies

 

Monitoring response to the therapeutic antibody

Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
80997Flow Cytometry, Cell Surface, FirstNo, (Bill Only)No
81047Flow Cytometry, Cell Surface, AddlNo, (Bill Only)No
88465Flow Cytometry Interp, 2-8 MarkersNo, (Bill Only)No
88466Flow Cytometry Interp, 9-15 MarkersNo, (Bill Only)No
88467Flow Cytometry Interp,16 or greaterNo, (Bill Only)No

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

When a blood or bone marrow is ordered, a panel specific to the desired antibody and a professional interpretation will always be charged. The panel will be charged based on number of markers tested (80997 for first marker, 81047 for each additional marker). The interpretation will be based on markers tested in increments of 2 to 8, 9 to 15, or 16 and greater.

Method Name A short description of the method used to perform the test

Immunophenotyping

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Therapeutic Antibody Evaluation

Aliases Lists additional common names for a test, as an aid in searching

Alemtuzumab (Campath) (CD52)
Campath-1H (CD52)
CD20
CD52
Ibritumomab Tiuxetin (Zevalin) (CD20)
IDEC-Y2B (CD20)
Rituximab (Rituxan) (CD20)
Tositumomab (Bexxar) (CD20)